Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial

<p>Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD).</p> <p>This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in moderate-to-severe AD patients with or without previous systemic treatments....

全面介紹

Saved in:

書目詳細資料
主要作者:	Qingchun Diao (5751701) (author)
其他作者:	Ruiling Jia (22654733) (author), Min Li (12799) (author), Peng Zhao (128233) (author), Fang Lu (45632) (author), Qin Zhang (58638) (author), Chunzhu Ning (22680917) (author), Juan Long (4017317) (author), Jiajia Li (184267) (author), Yan Huang (46805) (author), Yuyi Wang (462133) (author)
出版:	2025
主題:	Medicine Pharmacology Biotechnology Science Policy Biological Sciences not elsewhere classified Ivarmacitinib moderate-to-severe atopic dermatitis previous systemic treatments efficacy safety
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

成為第一個發表評論!

Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial

相似書籍